Market Overview

Benzinga's Top Downgrades

Share:
Benzinga's Top Downgrades
Related HTWR
Contemporary Results From Commercial HVAD System Registries Highlighted At ISHLT Meeting
18 Biotech Stocks These Wall Street Analysts Are Tracking
Related MSFT
Tech Tumble Sparks Volume Surge In Leveraged ETFs
Here's What Trip Chowdhry Likes After The Market Selloff
An 80/20 Filter On How The DJIA Weathered The Week (Seeking Alpha)

Analysts at Goldman Sachs downgraded Heartware International (NASDAQ: HTWR) from “neutral” to “sell.” The target price for Heartware International has been lowered from $94 to $73. Heartware's shares closed at $81.26 on Friday.

Analysts at Deutsche Bank downgraded Microsoft (NASDAQ: MSFT) from “buy” to “hold.” The target price for Microsoft is set to $42. Microsoft's shares closed at $39.21 on Friday.

Morgan Stanley downgraded Mindray Medical International (NYSE: MR) from “overweight” to “equal-weight.” The target price for Mindray Medical has been lowered from $44 to $37. Mindray Medical's shares closed at $33.08 on Friday.

Analysts at Credit Suisse downgraded Enbridge (NYSE: ENB) from “outperform” to “neutral.” Enbridge's shares closed at $46.60 on Friday.

Latest Ratings for HTWR

DateFirmActionFromTo
Aug 2015Credit SuisseAssumesOutperform
Jul 2015Leerink SwannMaintainsOutperform
Jul 2015BarclaysMaintainsOverweight

View More Analyst Ratings for HTWR
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (HTWR + ENB)

Get Benzinga's Newsletters